Cross-Sector entity

John L. Durnell

Person
7

John L. Durnell is most often covered alongside Bayer AG, which appears in 2 of these 2 stories. Coverage clusters in court-decisions, which accounts for 1 of those 2, with the remainder spread across 1 other category. The tracked stories average 2 original sources each.

2 verified stories tracked

Last mentioned: Jun 30, 2026

Entity pulse

Recent coverage · John L. Durnell

2 stories
7 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about John L. Durnell

John L. Durnell is most often covered alongside Bayer AG, which appears in 2 of these 2 stories. Coverage clusters in court-decisions, which accounts for 1 of those 2, with the remainder spread across 1 other category. The tracked stories average 2 original sources each. John L. Durnell appears in 2 tracked Cross-Sector stories from June 30, 2026.

Stories tracked
2
Sources per story
2

Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering John L. Durnell. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning John L. Durnell 2

Legal court decisions Neutral 7

FIFRA Preemption Win: 7-2 SCOTUS Reversal Slashes Roundup Tort Risk

The Supreme Court's 7-2 decision in Monsanto v. Durnell expressly preempts state failure-to-warn claims against pesticide labels approved by EPA. The ruling resolves a circuit split and provides a robust preemption defense for manufacturers, marking a significant shift in product liability litigation under FIFRA.

2 sources
Biotech fda approval Neutral 7

Roundup Ruling: 7-2 SCOTUS Verdict Reduces Bayer's Liability by Billions

The U.S. Supreme Court ruled that FIFRA preempts state failure-to-warn claims against Bayer's Roundup, eliminating a massive source of litigation uncertainty. The 7-2 decision validates EPA's safety assessment of glyphosate and sharply reduces Bayer's outstanding tort exposure, potentially freeing up billions in capital for the biotech giant.

2 sources

Source: National Law Review · National Law Review